Search - tctmd.com

Displaying 541 - 560 of 621

Sort: Relevancy | Date

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Industry News

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

June 05, 2015

News Conference News EuroPCR 2015

Evolving DES Technology May Benefit Diabetic Patients

Caitlin E. Cox

May 19, 2015

News Daily News

Un Estudio de ‘Pacientes No Seleccionados’ Revela un Beneficio sobre la Supervivencia derivado de Revascularizaciones Completas en Pacientes Con y Sin Diabetes

Caitlin E. Cox

May 08, 2015

News Daily News

“所有患者”研究表明完全血运重建能改善有或无糖尿病患者的生存率

Caitlin E. Cox

May 08, 2015

News Daily News

‘All-Comers’ Study Shows Survival Benefit of Complete Revascularization in Patients With, Without Diabetes

Caitlin E. Cox

May 08, 2015

News Daily News

住院急性心梗患者的糖尿病经常不易被发现

May 07, 2015

News Daily News

Diabetes Suele Pasar Desapercibida en Pacientes Hospitalizados con IAM

May 07, 2015

News Daily News

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

May 07, 2015

News Daily News

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

L.A. McKeown

February 22, 2015

News Daily News

CREDO-Kyoto: Diabetic Patients With 3-Vessel or Left Main Disease Fare Better With CABG

February 08, 2015

News Daily News

SORT OUT III亚组研究揭示了DES疗效随糖尿病状态的变化

Todd Neale

November 17, 2014

News Daily News

SORT OUT III Substudy Hints at Differences in DES Efficacy Based on Diabetes Status

Todd Neale

November 17, 2014

News Daily News

El Subestudio SORT OUT III Apunta a Diferencias en la Eficacia de los Stents Liberadores de Fármacos (SLF) según el Estado Diabético

Todd Neale

November 17, 2014

Advertisement

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Takeda Presents Additional Data from Alogliptin's EXAMINE Cardiovascular Safety Outcomes Trial at the American Diabetes Association's 75th Scientific Sessions

Evolving DES Technology May Benefit Diabetic Patients

Un Estudio de ‘Pacientes No Seleccionados’ Revela un Beneficio sobre la Supervivencia derivado de Revascularizaciones Completas en Pacientes Con y Sin Diabetes

“所有患者”研究表明完全血运重建能改善有或无糖尿病患者的生存率

‘All-Comers’ Study Shows Survival Benefit of Complete Revascularization in Patients With, Without Diabetes

住院急性心梗患者的糖尿病经常不易被发现

Diabetes Suele Pasar Desapercibida en Pacientes Hospitalizados con IAM

Diabetes Often Goes Unrecognized in Patients Hospitalized With Acute MI

Vorapaxar可对先前患过心梗的糖尿病患者起到有效的二级预防作用

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

CREDO-Kyoto: Diabetic Patients With 3-Vessel or Left Main Disease Fare Better With CABG

SORT OUT III亚组研究揭示了DES疗效随糖尿病状态的变化

SORT OUT III Substudy Hints at Differences in DES Efficacy Based on Diabetes Status

El Subestudio SORT OUT III Apunta a Diferencias en la Eficacia de los Stents Liberadores de Fármacos (SLF) según el Estado Diabético

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content